October 23, 2015 in News from Our Companies

Rimidi selected to present diabetes management findings at Diabetes Technology Meeting

Post placeholder image
http://atdc.org/companies/rimidi-diabetes/
Dr. Lucienne Ide is co-founder and chief executive of Atlanta-based Rimidi.

The Diabetes Technology Society has selected Rimidi and Desert Oasis Healthcare (DOHC) to present their abstract “Early Results Support Efficacy and Clinical Efficiency of Diabetes Management Decision Support Software for Blood Glucose Control” for presentation at the 15th Annual Diabetes Technology Meeting in Bethesda, Md., Oct. 22-24.

The abstract discusses initial study results indicating that patients who used Rimidi’s decision support software tool, Diabetes+Me, with standard of care pharmacist intervention, were able to lower their blood sugar and cholesterol levels more significantly than those with only the standard of care treatment.

An ATDC Signature company, Atlanta-based Rimidi is a a digital health company bringing to market data analytics and disease management solutions. Dr. Lucienne Ide is president and CEO.

The study, which is ongoing, compares three groups of 43 patients. The non-Rimidi arm receives the standard of care with pharmacist intervention. The Rimidi arm receives the standard of care with pharmacist intervention, in addition to the use of Diabetes+Me. Results will also be compared to a primary care arm.

The abstract is authored by Ide, Lindsey Valenzuela, PharmD BCACP, Dr. Michael Jardula, Dr. Mena Salib, and Jade Le, PharmD BCACP of DOHC.

For those in the Rimidi arm, an average absolute drop of 5.32 percent in HbA1c was noted at 12 weeks, versus an average decrease of only 3.04 percent in those with standard treatment. Additionally, there was a greater average drop in total cholesterol of 88.5 mg/dL in those in the Rimidi arm versus only 37.25 mg/dL in those with standard treatment.

“This demonstrates that not only will Rimidi offer assistance in regulating DM (diabetes management), it will also aid in managing cholesterol control, depicting the versatility of a Diabetes Decision (Support) Software,” the authors wrote, cautioning that the results are “preliminary” and represent “an interesting and hopeful trend in favor of the Diabetes+Me tool.”

The initial results showed larger reductions in HbA1c, total cholesterol, and LDL at both 4 and 8 weeks in the Rimidi arm versus the non-Rimidi arm.

“This finding highlights the added utility of the Diabetes+Me tool to quickly achieve target goals allowing for more patients to be treated over time further scaling efforts without the need to further increase the number of pharmacists,” the authors wrote.

Previous studies have shown that every one percent drop in HbA1c translates into a 14 percent reduction in heart attacks and a 33 percent reduction in the incidence of micro vascular complications from diabetes, the abstract noted.

“Early results in this study indicate that Diabetes+Me helps to ensure a safe, but meaningful reduction in A1c and therefore a reduction in event rate as well as overall healthcare costs,” the authors conclude. “Diabetes+Me has not only led to improved benefits to patients, but has also allowed Desert Oasis Healthcare to expand the scalability of its already successful diabetes management program without having to make the expensive investment of hiring additional healthcare providers.”

More than 29 million people — or 9.3 percent of the population — are estimated to have diabetes and almost 2 million new diagnoses are made yearly. In addition, 86 million adults aged 20 years and older have prediabetes, according to the Centers for Disease Control and Prevention in Atlanta.

Numerous studies have demonstrated that disease management programs can im¬prove clinical factors such as HbA1c and lipid levels and blood pressure. These clinical improvements contribute to better quality of life and significantly lower health care costs, the abstract noted.




By browsing this website, you agree to our privacy policy.
I Agree